AI
Thursday, November 29, 2012 5:04:30 AM
ARIA. ARIAD Announces Publication of Ponatinib Phase 1 Clinical Trial Results in the New England Journal of Medicine
Results demonstrate that ponatinib is highly active in heavily pretreated patients with CML and Ph + ALL
http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1762703&highlight=
Results demonstrate that ponatinib is highly active in heavily pretreated patients with CML and Ph + ALL
http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1762703&highlight=
The Nooner.
http://investorshub.advfn.com/The-Nooner-21519/
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
